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Both prospective and retrospective studies indicate that in
primary immunosuppressive therapy of severe aplastic ane-
mia (SAA), the use of horse antithymocyte globulin (hATG)
results in higher response rates and better long term out-
comes than rabbit ATG (rATG). However, rATG results inmore
profound and durable immunosuppression than hATG; thus,
the relative beneﬁt might be different when used in the
setting of transplantation conditioning. We previously
showed that bone marrow (BM) is a preferable stem cell
source to PBSC in SAA (Eapen et al Blood. 2011), andwe limited
this analysis to patients given BM.We analyzed the outcomes
of 699 SAA patients registered between 2007 and 2011 with
the CIBMTR who were transplanted from HLA-identical
sibling (MRD) or unrelated donors (URD) and received ATG as
part of the conditioning regimen. Patient characteristics are
shown in Table 1. Patients with URD transplants had a longer
delay fromdiagnosis andweremore likely to receive lowdose
TBI-based conditioning.
The proportions of patients achieving an ANC of 500/mL by 28
days were similar with rATG and hATG: MRD 90 vs. 88%
(p¼0.52), and URD, 86 vs. 90% (p¼0.30). The corresponding
incidence of platelet recovery by 100 days was 94 vs. 95% and
86 vs. 75%, respectively. However, the incidence of grades II-
IV acute GVHD by day 100 was lower with rATG than with
hATG for both MRD: 2 vs. 15% (p¼0.01) and with URDRelated Unrelated
hATG rATG hATG rATG
N 214 233 88 164
Male n (%) 121 (57) 130 (56) 46 (52) 91 (55)
Median age (range) 16 (1e68) 19 (2e65) 20 (1e66) 17 (1e67)
Diagnosis to BMT
<6 months 169 (79) 163 (70) 12 (14) 31 (19)
6 e 12 months 22 (10) 42 (18) 39 (44) 48 (29)
 1 year 23 (11) 28 (12) 37 (42) 84 (51)
Conditioning
Cy/ATG 198 (93) 168 (72) 8 (9) 2 (1)
Cy/ATG/Flu 16 (7) 65 (28) 9 (10) 45 (27)
Cy/ATG/TBI (3-8Gy) __ __ 4 (5) 5 (3)
Cy/ATG/TBI (2Gy) __ __ 38 (43) 30 (18)
Cy/ATG/Flu/TBI (2Gy) __ __ 28 (32) 70 (43)
ATG /other __ __ 1 (1) 12 (7)
GVHD Prophylaxis, N (%)
Tacrolimus-containing 63 (29) 49 (21) 36 (41) 58 (35)
Cyclosporine-containing 151 (71) 184 (79) 52 (59) 106 (65)transplants 23 vs. 43% (p¼0.06). Chronic GVHD was lower
with rATG at 1-year in MRD 5 vs. 12% (p¼0.02), but both
products gave similar risks of cGVHD in URD 16 vs. 14%
(p¼0.63). Overall cGVHD risk was low, and there was no
signiﬁcant difference at 3 years: MRD 9 vs. 13% (p¼0.25) and
URD 19 vs. 21% (p¼0.75). Survival at 100 days was better with
hATG in MRD transplants 97 vs. 94% (p¼0.05) but not URD
transplants 88 vs. 83% (p¼0.25). However,1 year survival was
similar with both ATG formulations in MRD 92 vs. 92%
(p¼.92) and in URD 80 vs. 71% (p¼0.16), although in both
settings rATG was slightly superior. Thus, rATG use leads to
signiﬁcantly less aGVHD in both MRD and URD trans-
plantation. While an advantage in survival was noted in URD
receiving rATG, at the power of this study statistical signiﬁ-
cance was not achieved.8
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An elevated serum ferritin before allogeneic stem cell
transplantation (HSCT) is an adverse prognostic factor for
overall survival (OS) and non-relapse mortality (NRM); but
because ferritin is an imperfect surrogate of iron stores, the
exact prognostic role of iron overload remains unproven.
Four prospective studies using liverMRI to estimate liver iron
content (LIC) have examined the impact of elevated LIC on
HSCT outcome (Armand et al. Am J Hematol. 2012;87(6):569,
Wermke et al. Clin Cancer Res. 2012;18(23):6460, Virtanen et
al. Eur J Haematol. 2013;91(1):85, Trottier et al. Blood.
2013;122(9):1678), but have reached different conclusions
on the prognostic relevance of LIC in HSCT. We therefore
conducted an individual patient data meta-analysis of those
4 studies, using a random effects model. The outcomes of
interest were OS and NRM. 276 patients were included in this
analysis. The median serum ferritin pre-HSCT was 1523
(range, 20-8,878) ng/ml, and the median LIC was 5.0 (range,
0.3-25.4) mg/gdw. 38% of patients received a myeloablative
conditioning regimen. With a median follow-up of 22
months for survivors, the estimated 2-year OSwas 62% (95CI,
55-68), and the NRM was 25% (95CI, 20-31). The pooled
hazard ratio (HR) for mortality associated with a pre-HSCT
LIC>7 mg/gdw (the primary endpoint) was 1.39 (95CI, 0.85-
2.27), p¼0.18 (Figure 1A). The pooled hazard ratio (HR) for
mortality associated with a pre-HSCT ferritin >1000 ng/ml
was 1.68 (95CI, 1.03-2.73), p¼0.036 (Figure 1B). There was no
signiﬁcant association between LIC>5 mg/gdw and OS, or
between ferritin>2500 ng/ml and OS. The signiﬁcant
Figure 1. Forest plot of the hazard ratios for mortality associated with LIC>7 mg/gdw (Panel A) and ferritin>1000 ng/ml (Panel B).
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in the subgroup of patients with MDS or acute leukemia, as
did the absence of signiﬁcant association between OS and
LIC. There was also no signiﬁcant association between LIC
and OS among patients conditioned with a myeloablative
regimen. In analyses of NRM, there was a trend towards
increased NRM for LIC>7 mg/gdw (HR¼1.74, p¼0.09) and for
ferritin>1000 ng/ml (HR¼1.55, p¼0.14) but neither reached
statistical signiﬁcance. There was no signiﬁcant association
between elevated ferritin or LIC and NRM among patients
who received a myeloablative conditioning or among acute
leukemia/MDS patients. In conclusion, despite the conﬁrmed
adverse prognosis conferred by pre-HSCT hyperferritinemia,
our meta-analysis suggests that iron overload, as assessed by
MRI-determined liver iron content, is not a signiﬁcant factor
for OS or NRM. This raises the possibility that the deleterious
prognostic impact of ferritin on survival is related to other
issues such as inﬂammatory status, infection, or disease
characteristics. These results may inform future research on
the use of chelation therapy in HSCT.9
Less Acute Graft-Versus-Host Disease with Higher
Mycophenolate Dose in
Nelli Bejanyan 1, John Rogosheske 2, Todd Defor 3, Kelli Esbaum4,
Mukta Arora 5, Margaret L. MacMillan 6, John E. Wagner 7,
Daniel Weisdorf 8, Pamala Jacobson 9, Claudio G. Brunstein 10.
1Hematology, Oncology and Transplantation, University of
Minnesota, Minnepolis, MN; 2Inpatient Pharmacy, University of
Minnesota Medical Center, Fairview, Minneapolis, MN; 3BMT
Research Program, University of Minnesota, Minneapolis, MN;
4Department of Pharmacy, University of Minnesota Medical
Center, Minneapolis, MN; 5Hematology, Oncology and
Transplant, University of Minnesota, Minneapolis, MN;
6Pediatric Blood and Marrow Transplant Program, University of
Minnesota, Minneapolis, MN; 7Pediatric Blood and MarrowTransplantation, University of Minnesota, Minneapolis, MN;
8University of Minnesota, Minneapolis, MN; 9Experimental and
Clinical Pharmacology, University of Minnesota, Minneapolis,
MN; 10Medical Center, Clinical Trials Ofﬁce, University of
Minnesota, Minneapolis, MN
Mycophenolate mofetil (MMF) is commonly used in reduced
intensity conditioning (RIC) allogeneic hematopoietic cell
transplantation (HCT) for graft-versus-host disease (GVHD)
prophylaxis and to facilitate engraftment. We previously
reported that higher level of mycophenolic acid can be ach-
ieved with MMF administered at 3 g/day MMF as compared
to 2g/day dose in patients (pts) with RIC transplantation.
Thus, we retrospectively compared clinical outcomes of pts
with hematological malignancies undergoing myloablative
(MA, n¼147) and RIC (n¼265) double umbilical cord blood
HCT (dUCBT) who received MMF 2g (n¼139) vs. 3g (n¼273)
daily. In multiple regression analysis after adjusting for
conditioning regimen (NMA RR 1.98, 95%CI, 1.59-2.47;
p<0.01), HLA disparity (HLA-match 6/6 RR 1.84, 95%CI, 1.21-
2.82; p<0.01; 5/6 RR 1.05; 95%CI 0.83-1.33, p¼0.67; ref 4/6)
and infused CD34 dose ( 3.5 x107/kg RR 1.63, 95%CI 1.27-
2.09, p<0.01; ref <3.5x107/kg), MMF dosing was not an in-
dependent predictor of neutrophil engraftment (MMF 3 g RR
0.83, 95% CI 0.66-1.05; p¼0.12; ref MMF 2g). However, after
adjustment for gender (female RR 0.72, 95%CI 0.54-0.94;
p¼0.02) and conditioning (NMA RR 0.72, 95%CI 0.55-0.95;
p¼0.02), MMF 3 g/day led to 42% reduction in grade II-IV
acute GVHD rate (RR¼0.58, 95%CI 0.45-0.76; p<0.01). Higher
MMF dosewas not protective for chronic GVHD (RR 0.73, 95%
CI 0.48-1.11; p¼0.15). The effect of MMF dosing on the risk of
infections was evaluated by cumulative density function that
accounts for multiple infectious events in an individual pt.
When we studied the effect of MMF dose on frequency of
bacterial, fungal and viral infections using speciﬁc post-
transplant time intervals (Figure), MMF 2g/day resulted in
signiﬁcantly higher density of bacterial infections (8.37 vs.
6.07 per 1000 pt days, p<0.01) and total infectious events
